Pfizer announced on Sept. 2 the dosing of the first patients in a Phase III trial assessing a single dose of the company’s investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and older. One day earlier, Pfizer announced the initiation of a Phase II/III clinical study of 1,140 participants for an oral pill expected to be used in a broad population of Covid patients.
Novavax Inc. said on May 10 the company’s combined flu and Covid-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.
The U.S. drug regulator gave Moderna Inc. clearance to speed up output of the company’s Covid-19 vaccine by letting it fill a single vial with up to 15 doses, with the United States banking on rapid immunization to stem the spread of the deadly virus.
Nine great apes at the San Diego Zoo – four orangutans and five bonobos – made veterinary history in recent weeks as the world’s first non-human primates known to be vaccinated against Covid-19, zoo officials said.
Top U.S. infectious disease official Dr. Anthony Fauci said on Feb. 28 he was encouraging Americans to accept any of the three available Covid-19 vaccines, including the newly approved Johnson & Johnson shot.
California surpassed New York on Feb. 9 as the U.S. state with the most coronavirus deaths, a grim reminder of the pandemic’s toll even as the vaccine rollout and a sharp drop in new cases buoyed hopes of life eventually returning to normal.
Worldwide coronavirus cases surpassed 90 million on Jan. 11, according to a Reuters tally, as nations around the globe scramble to procure vaccines and continue to extend or reinstate lockdowns to fight new coronavirus variants.
As Operation Warp Speed – the Trump administration’s program to develop and distribute a Covid-19 vaccine – struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.
Experts at India’s drugs regulator recommended two coronavirus vaccines for emergency use: one developed by AstraZeneca and Oxford University, and the other backed by a state-run institute.
Global coronavirus infections surpassed the 75 million mark on Dec. 19, according to a Reuters tally, as several nations around the world begin vaccinating against the virus.
